Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
Hungary’s Egis Pharmaceuticals has bolstered its OTC portfolio in its domestic market with the acquisition of skin-care brand Neogranormon from Teva Pharmaceutical Industries for an undisclosed sum.
The acquired Neogranormon portfolio is led by a zinc oxide-based ointment approved as an OTC drug in Hungary, which is said by Egis to stimulate the healing of skin injuries...
Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.
